Related Experiment Video
Updated: May 12, 2026
03:32
Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024
Phase II study on lapatinib in advanced EGFR-positive chordoma
S Stacchiotti1, E Tamborini2, S Lo Vullo3
1Sarcoma Unit, Departments of Cancer Medicine.
Summary
Lapatinib showed modest antitumor activity in advanced chordoma patients with epidermal growth factor receptor (EGFR) positivity. Further research is needed to explore EGFR targeting in chordoma treatment.
Area of Science:
- Oncology
- Molecular targeted therapy
- Chordoma research
Background:
- Chordoma is a rare bone tumor.
- Epidermal growth factor receptor (EGFR) is a potential therapeutic target in chordoma.
Purpose of the Study:
- To evaluate the efficacy and safety of lapatinib in patients with advanced chordoma.
- To assess the response rate and survival outcomes in this patient population.
Main Methods:
- A prospective, investigator-driven, phase II study.
- 18 patients with advanced chordoma received lapatinib.
- EGFR expression and activation were assessed.
- Response was evaluated using Choi criteria and RECIST.
Main Results:
- A response rate of 33.3% (partial response) and 38.9% (stable disease) by Choi criteria was observed.
- Median progression-free survival was 6 months (Choi) and 8 months (RECIST).
- A clinical benefit rate of 22% was reported.
Conclusions:
- Lapatinib demonstrated modest antitumor activity in advanced chordoma.
- EGFR targeting warrants further clinical and preclinical investigation in chordoma.
- This study provides valuable data for future chordoma treatment strategies.
